EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sierra Oncology's Enterprise Value is $1,074.42 Mil.
Sierra Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2022 was $-87.80 Mil. Therefore, Sierra Oncology's EV-to-FCF for today is -12.24.
The historical rank and industry rank for Sierra Oncology's EV-to-FCF or its related term are showing as below:
SRRA'
s EV-to-FCF Range Over the Past 10 Years
Min: -12.24 Med: -2.34 Max: -0.04
Current: -12.24
During the past 9 years, the highest EV-to-FCF of Sierra Oncology was -0.04. The lowest was -12.24. And the median was -2.34.
SRRA's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 6.365
vs SRRA: -12.24
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Sierra Oncology's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sierra Oncology's EV-to-FCF
For the Biotechnology subindustry, Sierra Oncology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sierra Oncology's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sierra Oncology's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sierra Oncology's EV-to-FCF falls into.
Sierra Oncology's current Enterprise Value is $1,074.42 Mil.
Sierra Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-87.80 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sierra Oncology (NAS:SRRA) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Sierra Oncology's PE Ratio for today is calculated as:
Sierra Oncology's share price for today is $54.99.
Sierra Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.770.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sierra Oncology EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Sierra Oncology's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Sierra Oncology (Sierra Oncology) Business Description
Sierra Oncology Inc is a clinical-stage drug development company. It focuses on the research, development, and commercialization of DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. In addition, it also engaged in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in the preclinical development stage.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SRRA has been successfully added to your 